J&J agrees to Propulsid settlement
A Johnson & Johnson Propulsid litigation settlement will become effective once 85% of the death claims agree to its terms, J&J's Janssen division announced Feb. 5. J&J will pay between $69.5 mil. and $90 mil., depending on how many plaintiffs enroll in the program. The federal multi-district litigation includes approximately 4,000 plaintiffs, 300 of whom are alleged to have died from use of the drug. J&J ceased marketing Propulsid (cisapride) in 2000; the gastrointestinal agent is currently available through a limited access program...
You may also be interested in...
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.